Quantcast

Oral bisphosphonate use and risk of postmenopausal endometrial cancer.

Research paper by Polly A PA Newcomb, Michael N MN Passarelli, Amanda I AI Phipps, Garnet L GL Anderson, Jean J Wactawski-Wende, Gloria Y F GY Ho, Mary Jo MJ O'Sullivan, Rowan T RT Chlebowski

Indexed on: 26 Feb '15Published on: 26 Feb '15Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology



Abstract

Bisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer.We evaluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. All women had an intact uterus at the time of study entry.During a median follow-up of 12.5 years, 1,123 women were diagnosed with incident invasive endometrial cancer. Ever use of bisphosphonates was associated with reduced endometrial cancer risk (adjusted hazard ratio, 0.80; 95% CI, 0.64 to 1.00; P = .05), with no interactions observed with age, body mass index, or indication for use.In this large prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk.